2023-10-20 13:28:12
Already listed on the Paris Stock Exchange, the biotech announces its listing on Wall Street this Friday. Specializing in chronic inflammatory diseases, Abivax hopes to raise 250 million euros to finance the continuation of phase III clinical trials of its drug once morest ulcerative colitis.
Do all roads lead to Wall Street? After Nanobiotix in 2020, it is the turn of the French biotechnology company Abivax, listed on the Paris Stock Exchange, to announce its IPO in New York this Friday. A specialist in chronic inflammatory diseases, the biotech hopes to raise 250 million euros through a double listing on the American Stock Exchange and a private placement in Europe.
The listing on Wall Street marks a turning point for the firm created in 2013 by Philippe Pouletty, managing director of Truffle Capital…
This article is reserved for subscribers. You have 91% left to discover.
Flash Sale €1.99/month for 6 months
Offer available until October 23. Without engagement.
Already subscribed? Log in
1697811156
#Abivax #French #biotech #nugget #raising #million #euros #Wall #Street
